hrp0097p2-176 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

A patient-centred and multi-stakeholder co-designed, mixed methods, observational, prospective study protocol: Example of the adolescent experience of treatment for X-linked hypophosphatemia (XLH)

Saraff Vrinda , Arango-Sancho Pedro , Bacchetta Justine , M. Boot Annemieke , P. Burren Christine , Chinoy Amish , Dharmaraj Poonam , David González-Rodríguez Juan , Gueorguieva Iva , Hayes Wesley , Linglart Agnès , Amelia Gómez Llorente Maria , Ríos Héctor , Schnabel Dirk , Harvengt Pol , M.A. Bailey Karen , Glen Fiona , J. Rylands Angela , Williams Angela , Haf Davies Elin

Background: XLH is a rare, genetic, life-long disease caused by PHEX pathogenic variants. It is associated with progressive accumulation of musculoskeletal features and symptoms that evolve across the patient’s lifetime if untreated. Although the disease is well characterised in children and adults, there are limited data describing the health outcomes and experiences of adolescents, particularly at end of skeletal growth (EOSG), a crucial phase during t...

hrp0098p1-116 | Bone, Growth Plate and Mineral Metabolism 2 | ESPE2024

Health related quality of life (HRQoL) of adolescents with XLH treated with burosumab at the end of skeletal growth (EoSG.

Saraff Vrinda , Arango Sancho Pedro , Bacchetta Justine , Linglart Agnès , Burren Christine , Chinoy Amish , Dharmaraj Poonam , Amelia Gómez Llorente Maria , David González Rodríguez Juan , Gueorguieva Iva , Haf Davies Elin , Hayes Wesley , Komarzynski Sandra , Ríos Duro Héctor , J Rylands Angela , Sandilands Kerry , Hardie Emily , Ishii Haruka , Schnabel Dirk , Selveindran San , M Boot Annemieke

Introduction: X-linked hypophosphatemia (XLH) is a rare, progressive, genetic disorder causing phosphate wasting; hence symptoms in children include impaired growth, lower limb deformities, chronic pain and impaired physical function. Health-related quality of life (HRQoL) of patients with XLH on conventional therapy is lower than that of the general population. Burosumab has been shown to improve HRQoL in younger children and adults, but its effects in adoles...

hrp0089p1-p152 | GH & IGFs P1 | ESPE2018

Microalbuminuria and Glomerular Filtration Rate in SGA Born Young Adults

Goedegebuure Wesley , Hokken-Koelega Anita

Background: Following Barker’s hypothesis on fetal growth retardation, low birth weight and being born small for gestational age (SGA) might be linked to fewer glomeruli which influences adult disease. Growth hormone (GH) treatment leads to a greater kidney length and total kidney volume, as well as a higher glomerular filtration rate (GFR). Microalbuminuria, defined as more than 20 mg/l albumin in random urine sample, is a marker for renal diseases and is a risk factor f...

hrp0092p1-366 | GH and IGFs (2) | ESPE2019

Glomerular Filtration Rate in Young Adults Born SGA: A 5-Year Longitudinal Study after Cessation of GH Treatment.

Goedegebuure Wesley , Kerkhof Gerthe , Hokken-Koelega Anita

Background: GH treatment increases glomerular filtration rate (GFR), as serum IGF-I stimulates the renin-angiotensin system. Data on longitudinal changes in GFR after cessation of GH treatment in young adults born small for gestational age (SGA) are not available. It is essential to ascertain longitudinal data after cessation of GH treatment, to evaluate the possible long-term effects of higher serum IGF-I levels during childhood treatment on adult GFR.<p ...

hrp0097p1-231 | Diabetes and Insulin | ESPE2023

Children with Type 1 Diabetes and Obesity show biochemical changes associated with insulin resistance

Hayes Eadaoin , Cody Declan , E Hogan Andrew

Children with Type 1 diabetes are experiencing higher levels of overweight and obesity as a consequence of intensive insulin therapy as well as background socioeconomic and environmental factors that are contributing to excess adiposity in the general population. The consequences of obesity in people with type 1 diabetes are of particular concern, as obesity in adults increases the risk of both diabetes-related and obesity-related complications, including cardiovascular diseas...

hrp0095rfc10.5 | GH and IGFs | ESPE2022

Evaluation of health-related quality of life & problem behavior in adults born small for gestational age treated with growth hormone during childhood in comparison with untreated controls

Dorrepaal Demi , Wesley Goedegebuure , der Steen Manouk van , Anita Hokken-Koelega

Background: Being born small for gestational age (SGA) has been associated with a reduction in health-related quality of life (HRQoL) and more problem behaviour. Growth hormone (GH) treatment, which leads to a significant improvement in adult height (AH), improves HRQoL and decreases problem behavior in SGA children. However, such results are very limited in SGA adults who were treated with GH during childhood.Objective:...

hrp0089p2-p225 | GH &amp; IGFs P2 | ESPE2018

Health-Related Quality of Life and Psychosocial Functioning in Young Adults Born SGA after GH/GnRHa Treatment

Goedegebuure Wesley , van der Steen Manouk , de With Justine , Hokken-Koelega Anita

Background: Being born small for gestational age (SGA) has a negative effect on health-related quality of life (HRQoL) and self-perception. This might be more negatively influenced by postponement of puberty using additional gonadotropin-releasing hormone analogue (GnRHa) treatment.Methods: 154 adolescents born SGA participating in a large Dutch growth hormone (GH) trial (75 with 2 years of GnRHa-treatment) completed the TNO-AZL Adults Quality of Life qu...

hrp0086p1-p805 | Syndromes: Mechanisms and Management P1 | ESPE2016

Percutaneous Epiphysiodesis Around the Knee Effectively Reduced Predicted Excessive Final Height. Preliminary Results on Final Height, Complications and Satisfaction in a Large Cohort of Dutch Boys and Girls

Goedegebuure Wesley , van der Steen Marieke , Jonkers Frank , Bakker-van Waarde Willy , Odink Roelof

Background: Percutaneous epiphysiodesis (PE) around the knee is the treatment of choice in the Netherlands to reduce predicted excessive final height. Studies until now are limited, had small numbers of patients and short follow-up periods.Objective and hypotheses: This nationwide Dutch long-term retrospective follow-up study aimed to assess final height (FH), complications and satisfaction after PE. Primary hypothesis was: ‘The PE around the knee i...

hrp0097rfc11.3 | GH and IGFs | ESPE2023

Longitudinal assessment of health-related quality of life (HRQoL) & behavior in adults born small for gestational age (SGA) who were treated with growth hormone during childhood

Dorrepaal Demi , Goedegebuure Wesley , de Ridder Maria , van der Steen Manouk , Hokken-Koelega Anita

Background: Short stature has been associated with a reduction in health-related quality of life (HRQoL) and more problem behavior in children and adults. In adolescents who were treated with growth hormone (GH) because of persistent short stature after being born SGA, an increase in HRQoL and decrease in behavioral problems was seen during or right after cessation of GH-treatment. However, long-term data, to analyze if these positive effects remain many years...

hrp0095fc10.4 | GH and IGFs | ESPE2022

Cerebral white matter hyperintensities in young adults born small for gestational age treated with growth hormone during childhood in comparison with untreated controls

Dorrepaal Demi , Goedegebuure Wesley , Bos Daniel , van der Lugt Aad , van der Steen Manouk , Hokken-Koelega Anita

Background: The French population of the SAGhE study showed an increased morbidity and mortality due to cerebrovascular disease in growth hormone (GH) treated subjects compared to the general population. Cerebrovascular health can be assessed using neuroimaging markers on MRI. One of the markers is white matter hyperintensity (WMH).Objective: To assess cerebrovascular health by scoring WMH on MRI in young adults born sma...